Biosimilar vs originator insulins: Systematic review and meta‐analysis

• 資料種別: 記事
• タイトル: Biosimilar vs originator insulins: Systematic review and meta‐analysis
• 著者標目: Tomohide Yamada; Ryuichi Kamata; Kotomi Ishinohachi; Nobuhiro Shojima; Sophia Ananiadou; Hisashi Nom; Toshimasa Yamauchi; Takashi Kadowaki
• 出版年月日等: 2018-04-17
• 出版年（W3CDTF）: 2018-04-17
• タイトル（掲載誌）: Diabetes, Obesity and Metabolism
• 巻号年月日等（掲載誌）: 20 7
• 掲載巻: 20
• 掲載号: 7
• 掲載ページ: 1787-1792
• 掲載年月日（W3CDTF）: 2018-04-17
• ISSN（掲載誌）: 14628902
• 出版事項（掲載誌）: Wiley
• 件名標目: Blood Glucose; Glycated Hemoglobin; Insulin Lispro; Insulin Antibodies; Insulin Glargine; Hypoglycemia; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Biosimilar Pharmaceuticals
• 対象利用者: 一般
• 標準番号（その他）: PMID : 29536603
• DOI: 10.1111/dom.13291; https://doi.org/10.1111/dom.13291
• 作成日（W3CDTF）: 2018-03-15
• 著作権情報: http://onlinelibrary.wiley.com/termsAndConditions#vor
• 関連情報（URI）: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.13291; https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13291; https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.13291; https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.13291
• 参照: Introduction of biosimilar insulins in Europe; https://cir.nii.ac.jp/crid/1360011144061497600; Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens; https://cir.nii.ac.jp/crid/1360855570543468416; Conducting Meta-Analyses in<i>R</i>with the<b>metafor</b>Package; https://cir.nii.ac.jp/crid/1361137043969836032; Reducing systematic review workload through certainty-based screening; https://cir.nii.ac.jp/crid/1361137046073026944; Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study; https://cir.nii.ac.jp/crid/1361699993895690880; Essential medicines for universal health coverage; https://cir.nii.ac.jp/crid/1361981469956936320; A semi-supervised approach using label propagation to support citation screening; https://cir.nii.ac.jp/crid/1362262944661277952; Similar efficacy and safety of <scp>LY2963016</scp> insulin glargine and insulin glargine ( <scp>L</scp> antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the <scp>ELEMENT</scp> 2 study); https://cir.nii.ac.jp/crid/1362262945660106368; Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study; https://cir.nii.ac.jp/crid/1362825893694342400; Constraints and challenges in access to insulin: a global perspective; https://cir.nii.ac.jp/crid/1363388844381042304; Multivariate Random-effects Meta-analysis; https://cir.nii.ac.jp/crid/1363670318733776640; Efficacy and safety of <scp>LY2963016</scp> insulin glargine compared with insulin glargine ( <scp>L</scp> antus®) in patients with type 1 diabetes in a randomized controlled trial: the <scp>ELEMENT</scp> 1 study; https://cir.nii.ac.jp/crid/1364233268538533120; Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications; https://cir.nii.ac.jp/crid/1364233269597173376; Efficacy and safety for insulin glargine biosimilar in patients with type 1 diabetes mellitus undergoing intensive insulin treatment; https://cir.nii.ac.jp/crid/1370004235504267523
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja

• 要約等: <jats:p> Biosimilar insulins have expanded the treatment options for diabetes. We compared the clinical efficacy and safety of bio...